Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Cancer

Figure 5

From: The direct effect of Focal Adhesion Kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis

Figure 5

Decreased tumorigenesis in vivo and gene expression analysis in MCF-7-FAKsiRNA model. A, Upper left panel, MCF-7, MCF-7-Vector, MCF-7-Control siRNA (firefly luciferase siRNA), MCF-7-FAKsiRNA#1 and FAKsiRNA#2 were injected into mice, and tumor volume was measured at different time points (1–30 days). FAKsiRNA #1 and #2 decreased tumor growth in vivo compared to MCF-7, MCF-7-Vector and MCF-7-Control siRNA cells. Bars show means of tumor growth measured at day 30 ± standard errors (n = 5 mice in each group). Lower left panel: Tumors from FAKsiRNA cells had significantly less weight than tumors from control MCF-7, MCF-7-Vector and MCF-7-Control siRNA group (measured at day 30). *, p < 0.05 FAKsiRNA#1 and FAKsiRNA#2 versus control cells. Right panel: Representative tumor sizes are shown from each group. B, Tumors collected at day 30 from MCF-7-FAKsiRNA mice express decreased levels of FAK. Western blotting was performed with FAK antibody. C, Profile of gene expression in FAKsiRNA cell lines with Affymetrix gene Chips. Microarray heat map of genes on MCF-7 cell lines is shown. Upregulated genes (green) and down-regulated (Red). Affymetrix gene Chip Human Genome U133A (two chips per sample) was used. More than 4300 genes (shown) up or down-regulated with p < 0.05 in FAKsiRNA#1 and FAKsiRNA#2 pooled group compared to MCF-7, MCF-7-Vector and MCF-7-Control siRNA pooled group.

Back to article page